Glenmark Pharma hits 52-week low on weak Q1 results; stock down 8%

Glenmark Pharma hits 52-week low on weak Q1 results; stock down 8% Earnings before interest, tax, depreciation and amortization (EBITDA) was down at Rs 341.9 crore, while margin fell 130 bps at 14.7 percent.
This entry was posted in Global India, Market News, News. Bookmark the permalink.

Comments are closed.